Stephanie Downs-Canner

Stephanie Downs-Canner

Auto-generated profile, based on publicly available information

Stephanie Downs-Canner

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SDStephanie Downs-Canner
Stephanie Downs-Canner
SBSara Berkey
Sara Berkey
GDGreg M. Delgoffe
Greg M. Delgoffe
RERobert P. Edwards
Robert P. Edwards
TCTyler Curiel
Tyler Curiel
NONataša Obermajer
Nataša Obermajer
Th17 and regulatory T (Treg) cells are integral in maintaining immune homeostasis and Th17–Treg imbalance is associated with inflammatory immunosuppression in cancer. Here we show that Th17 cells are a source of tumour-induced Foxp3+ cells. In addition to natural (n)Treg and induced (i)Treg cells that develop from naive precursors, suppressive IL-17A+Foxp3+ and ex-Th17 Foxp3+ cells are converted from IL-17A+Foxp3neg cells in tumour-bearing mice. Metabolic phenotyping of Foxp3-expressing IL-17A+, ex-Th17 and iTreg cells demonstrates the dissociation between the metabolic fitness and the suppressive function of Foxp3-expressing Treg cell subsets. Although all Foxp3-expressing subsets are immunosuppressive, glycolysis is a prominent metabolic pathway exerted only by IL-17A+Foxp3+ cells. Transcriptome analysis and flow cytometry of IL-17A+Foxp3+ cells indicate that Folr4, GARP, Itgb8, Pglyrp1, Il1rl1, Itgae, TIGIT and ICOS are Th17-to-Treg cell transdifferentiation-associated markers. Tumour-associated Th17-to-Treg cell conversion identified here provides insights for targeting the dynamism of Th17–Treg cells in cancer immunotherapy.

1 January 2015 in Molecular Therapy
Verified
Journal Article
Open access
HZHerbert J Zeh
Herbert J Zeh
SDStephanie Downs-Canner
Stephanie Downs-Canner
JMJ Andrea McCart
J Andrea McCart
Zong Sheng GuoZong Sheng Guo
Zong Sheng Guo
URUma N M Rao
Uma N M Rao
DBDavid L. Bartlett
David L. Bartlett
Oncolytic viral therapy utilizes a tumor-selective replicating virus which preferentially infects and destroys cancer cells and triggers antitumor immunity. The Western Reserve strain of vaccinia virus (VV) is the most virulent strain of VV in animal models and has been engineered for tumor selectivity through two targeted gene deletions (vvDD). We performed the first-in-human phase 1, intratumoral dose escalation clinical trial of vvDD in 16 patients with advanced solid tumors. In addition to safety, we evaluated signs of vvDD replication and spread to distant tumors, pharmacokinetics and pharmacodynamics, clinical and immune responses to vvDD. Dose escalation proceeded without dose-limiting toxicities to a maximum feasible dose of 3 × 10(9) pfu. vvDD replication in tumors was reproducible. vvDD genomes and/or infectious particles were recovered from injected (n = 5 patients) and noninjected (n = 2 patients) tumors. At the two highest doses, vvDD genomes were detected acutely in blood in all patients while delayed re-emergence of vvDD genomes in blood was detected in two patients. Fifteen of 16 patients exhibited late symptoms, consistent with ongoing vvDD replication. In summary, intratumoral injection of the oncolytic vaccinia vvDD was well-tolerated in patients and resulted in selective infection of injected and noninjected tumors and antitumor activity.

1 August 2016 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
SDStephanie Downs-Canner
Stephanie Downs-Canner
Zong Sheng GuoZong Sheng Guo
Zong Sheng Guo
RRRoshni Ravindranathan
Roshni Ravindranathan
CBCaroline J Breitbach
Caroline J Breitbach
MOMark E O'MAlley
Mark E O'MAlley
DBDavid L. Bartlett
David L. Bartlett
We have conducted a phase 1 study of intravenous vvDD, a Western Reserve strain oncolytic vaccinia virus, on 11 patients with standard treatment-refractory advanced colorectal or other solid cancers. The primary endpoints were maximum tolerated dose and associated toxicity while secondary endpoints were pharmacokinetics, pharmacodynamics, immune responses, and antitumor activity. No dose-limiting toxicities and treatment related severe adverse events were observed. The most common adverse events were grades 1/2 flu-like symptoms. Virus genomes were detectable in the blood 15–30 minutes after virus administration in a dose-dependent manner. There was evidence of a prolonged virus replication in tumor tissues in two patients, but no evidence of virus replication in non-tumor tissues, except a healed injury site and an oral thrush. Over 100-fold of anti-viral antibodies were induced in patients' sera. A strong induction of inflammatory and Th1, but not Th2 cytokines, suggested a potent Th1-mediated immunity against the virus and possibly the cancer. One patient showed a mixed response on PET-CT with resolution of some liver metastases, and another patient with cutaneous melanoma demonstrated clinical regression of some lesions. Given the confirmed safety, further trials evaluating intravenous vvDD in combination with therapeutic transgenes, immune checkpoint blockade or complement inhibitors, are warranted.

1 December 2009 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
SDStephanie Downs-Canner
Stephanie Downs-Canner
PSPeter H. Shaw
Peter H. Shaw
Over the past 30 years, there has been a dramatic increase in the survival rates of younger pediatric cancer patients in contrast to adolescent and young adult (AYA) oncology patients. The reasons for this discrepancy are multifactorial, but it is clear that clinical trial enrollment correlates with better outcomes. We examined the rate of clinical trial accrual of AYA oncology patients (aged 15 to 22 y) treated at affiliated pediatric and adult cancer centers, the Children's Hospital of Pittsburgh and the University of Pittsburgh Cancer Institute. We retrospectively analyzed all new cancer diagnoses and clinical trial enrollment status between 2003 and 2006 for AYA patients at both institutions. There were 91 new AYA cancer diagnoses at Children's Hospital of Pittsburgh, of which 24 (26%) were enrolled on a clinical trial. During the same time period, only 5 of 121 new AYA cancer patients (4%) at University of Pittsburgh Cancer Institute were enrolled on a clinical trial, which was significantly lower (P<0.001). Our data demonstrate that clinical trial enrollment was superior when AYA patients were treated at a pediatric cancer center. As most AYA patients are not treated at pediatric centers, this may partly explain why their cure rates have not improved as significantly as younger pediatric oncology patients.

7 July 2015 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SDStephanie Downs-Canner
Stephanie Downs-Canner
MZMazen Zenati
Mazen Zenati
Brian A. BooneBrian A. Boone
Brian A. Boone
PVPatrick R. Varley
Patrick R. Varley
JSJennifer Steve
Jennifer Steve
KLKenneth K.W. Lee
Kenneth K.W. Lee

20 August 2015 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SDStephanie Downs-Canner
Stephanie Downs-Canner
DMDeepa Magge
Deepa Magge
RRRoshni Ravindranathan
Roshni Ravindranathan
MOMark E. O’malley
Mark E. O’malley
LFLily Francis
Lily Francis
DBDavid L. Bartlett
David L. Bartlett